{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T21:36:01Z","timestamp":1781818561627,"version":"3.54.5"},"reference-count":72,"publisher":"American Medical Association (AMA)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Oncol"],"published-print":{"date-parts":[[2026,2,1]]},"abstract":"<jats:sec id=\"ab-coi250077-4\">\n                    <jats:title>Importance<\/jats:title>\n                    <jats:p>Fatigue is a common symptom reported by patients with cancer, yet its role as a predictor of treatment-related toxic effects has not been well characterized. Understanding whether fatigue measured at treatment initiation may be associated with subsequent toxic effects could help guide individualized treatment planning and symptom monitoring.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-coi250077-5\">\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To evaluate the association between baseline patient-reported fatigue and the risk of adverse events (AEs) in cancer treatment trials.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-coi250077-6\">\n                    <jats:title>Design, Setting, and Participants<\/jats:title>\n                    <jats:p>This cohort study and pooled analysis assessed baseline fatigue data from 17 SWOG phase 2 and 3 trials conducted from 1990 to 2022. Patients were enrolled across multiple cancer types and treatment settings. Data analysis was performed from March 1, 2023, to October 17, 2025.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-coi250077-7\">\n                    <jats:title>Exposures<\/jats:title>\n                    <jats:p>Baseline fatigue, classified on a 5-point Likert scale, analyzed as binary thresholds (eg, &amp;amp;lt;some vs\u2009\u2265some fatigue) and across fatigue severity levels.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-coi250077-8\">\n                    <jats:title>Main Outcomes and Measures<\/jats:title>\n                    <jats:p>Adverse events were classified using the Common Terminology Criteria for Adverse Events (CTCAE), with multiple versions mapped to version 4. Symptomatic AEs followed the Patient-Reported Outcomes-CTCAE framework; laboratory-based or measurable toxic effects were considered objective (hematologic vs nonhematologic). Primary outcomes were grade 3 or higher (severe), grade 4 or higher (life-threatening), and grade 5 (fatal) AEs. Odds ratios (ORs) were estimated using generalized estimating equations. To account for confounding, the analysis was clustered by trial and adjusted for age, sex, race, and obesity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-coi250077-9\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Among 7086 patients (mean [SD] age, 62.1 [15.2] years; 2107 females [29.7%] and 4979 males [70.3%]) with prostate, lung, colorectal, lymphoma, breast, melanoma, ovarian, or pancreatic cancer, 103\u202f738 AEs were reported. At baseline, 2771 participants (39.1%) reported\u2009some or more fatigue. Proportions with maximum AEs rated grade 3 or higher, grade 4 or higher, and grade 5 were 3128 participants (44.1%), 1001 (14.1%), and 62 (0.9%), respectively. Compared with those reporting no or minimal fatigue, patients with some fatigue or more had higher risks of severe or worse toxic effects (odds ratio [OR], 2.09; 95% CI, 1.58-2.78;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2009&amp;amp;lt;\u2009.001), life-threatening or fatal toxic effects (OR, 1.96; 95% CI, 1.36-2.82;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2009&amp;amp;lt;\u2009.001), and fatal toxic effects (OR, 2.35; 95% CI, 1.07-5.19;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2009=\u2009.03). A dose-response pattern was evident: patients reporting quite a lot or very much fatigue had an approximately 5-fold higher risk of fatal toxic effects (OR, 4.99; 95% CI, 1.84-13.51;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2009=\u2009.002). Findings were consistent across symptomatic, hematologic, and nonhematologic AE categories.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-coi250077-10\">\n                    <jats:title>Conclusions and Relevance<\/jats:title>\n                    <jats:p>This cohort study found that baseline patient-reported fatigue was associated with an increased risk of cancer treatment\u2212related toxic effects. Fatigue assessments at treatment initiation may serve as an early clinical marker of risk for toxic effects and may help inform personalized treatment strategies and symptom monitoring.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1001\/jamaoncol.2025.5549","type":"journal-article","created":{"date-parts":[[2025,12,26]],"date-time":"2025-12-26T16:30:45Z","timestamp":1766766645000},"page":"185","source":"Crossref","is-referenced-by-count":3,"title":["Baseline Fatigue and Severe Toxic Effects in Patients With Cancer Receiving Systemic Therapy"],"prefix":"10.1001","volume":"12","author":[{"given":"Joseph M.","family":"Unger","sequence":"first","affiliation":[{"name":"SWOG Statistics and Data Management Center, Fred Hutchinson Cancer Center, Seattle, Washington"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Fisch","sequence":"additional","affiliation":[{"name":"Carelon Specialty Care Solutions, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salene M. W.","family":"Jones","sequence":"additional","affiliation":[{"name":"SWOG Statistics and Data Management Center, Fred Hutchinson Cancer Center, Seattle, Washington"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N. Lynn","family":"Henry","sequence":"additional","affiliation":[{"name":"University of Michigan Medical School, Ann Arbor"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dawn L.","family":"Hershman","sequence":"additional","affiliation":[{"name":"Columbia University, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"9","key":"coi250077r1","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1038\/sj.bjc.6604739","article-title":"Severe fatigue and related factors in cancer patients before the initiation of treatment.","volume":"99","author":"Goedendorp","year":"2008","journal-title":"Br J Cancer"},{"issue":"4","key":"coi250077r2","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1002\/cncr.20423","article-title":"Cancer patients\u2019 expectations of experiencing treatment-related side effects: a University of Rochester Cancer Center\u2013Community Clinical Oncology Program study of 938 patients from community practices.","volume":"101","author":"Hofman","year":"2004","journal-title":"Cancer"},{"issue":"3","key":"coi250077r3","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1002\/cncr.28437","article-title":"Predictors of significant worsening of patient-reported fatigue over a 1-month timeframe in ambulatory patients with common solid tumors.","volume":"120","author":"Fisch","year":"2014","journal-title":"Cancer"},{"issue":"32","key":"coi250077r4","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1093\/jncimonographs\/lgh027","article-title":"Evidence report on the occurrence, assessment, and treatment of fatigue in cancer patients.","author":"Lawrence","year":"2004","journal-title":"J Natl Cancer Inst Monogr"},{"issue":"2","key":"coi250077r5","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1038\/bjc.1993.319","article-title":"Fatigue in cancer patients.","volume":"68","author":"Smets","year":"1993","journal-title":"Br J Cancer"},{"key":"coi250077r6","first-page":"1539","article-title":"\u201cBone tired\u201d: the experience of fatigue and its impact on quality of life.","volume":"23","author":"Ferrell","year":"1996","journal-title":"Oncol Nurs Forum"},{"issue":"8","key":"coi250077r7","doi-asserted-by":"crossref","first-page":"4989","DOI":"10.1158\/1538-7445.AM2025-4989","article-title":"Sex disparity in cancer-related fatigue, depression, and impact on quality of life among cancer survivors: insights from NHANES.","volume":"85","author":"Du","year":"2025","journal-title":"Cancer Res"},{"issue":"6","key":"coi250077r8","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1002\/1097-0142(20000915)89:6<1322::AID-CNCR18>3.0.CO;2-D","article-title":"Quality of life changes during conformal radiation therapy for prostate carcinoma.","volume":"89","author":"Janda","year":"2000","journal-title":"Cancer"},{"issue":"2","key":"coi250077r9","first-page":"82","article-title":"A qualitative study to explore the concept of fatigue\/tiredness in cancer patients and in healthy individuals.","volume":"4","author":"Glaus","year":"1996","journal-title":"Support Care Cancer"},{"issue":"1","key":"coi250077r10","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1054\/ejon.1999.0051","article-title":"An evaluation of the impact of a self-care coping intervention on psychological and clinical outcomes in adolescents with newly diagnosed cancer.","volume":"4","author":"Hinds","year":"2000","journal-title":"Eur J Oncol Nurs"},{"issue":"1","key":"coi250077r11","first-page":"20","article-title":"Fatigue in cancer patients: a review of the literature.","volume":"4","author":"Richardson","year":"1995","journal-title":"Eur J Cancer Care (Engl)"},{"issue":"3","key":"coi250077r12","first-page":"4","article-title":"Patient, caregiver, and oncologist perceptions of cancer-related fatigue: results of a tripart assessment survey. The Fatigue Coalition.","volume":"34","author":"Vogelzang","year":"1997","journal-title":"Semin Hematol"},{"key":"coi250077r13","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1002\/cncr.28058","article-title":"Cancer-related fatigue and its impact on functioning.","volume":"119","author":"Minton","year":"2013","journal-title":"Cancer"},{"issue":"24","key":"coi250077r14","doi-asserted-by":"crossref","first-page":"4333","DOI":"10.1002\/cncr.28376","article-title":"The symptom burden of cancer: evidence for a core set of cancer-related and treatment-related symptoms from the Eastern Cooperative Oncology Group Symptom Outcomes and Practice Patterns study.","volume":"119","author":"Cleeland","year":"2013","journal-title":"Cancer"},{"issue":"8","key":"coi250077r15","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.6004\/jnccn.2015.0122","article-title":"Cancer-related fatigue, version 2.2015.","volume":"13","author":"Berger","year":"2015","journal-title":"J Natl Compr Canc Netw"},{"issue":"8","key":"coi250077r16","doi-asserted-by":"crossref","first-page":"e1246","DOI":"10.1200\/OP.20.01096","article-title":"Association of fatigue and outcomes in advanced cancer: an analysis of four SWOG treatment trials.","volume":"17","author":"Mo","year":"2021","journal-title":"JCO Oncol Pract"},{"key":"coi250077r17","first-page":"97","article-title":"Prognostic significance of baseline fatigue for overall survival: a patient-level meta-analysis of 43 oncology clinical trials with 3915 patients.","volume":"12","author":"Sloan","year":"2017","journal-title":"Trends Cancer Res"},{"issue":"3","key":"coi250077r18","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2024.102941","article-title":"Under-reporting of subjective symptoms and its prognostic value: a pooled analysis of 12 cancer clinical trials.","volume":"9","author":"Arenare","year":"2024","journal-title":"ESMO Open"},{"issue":"8","key":"coi250077r19","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1093\/jnci\/djab015","article-title":"Underreporting of symptomatic adverse events in phase I clinical trials.","volume":"113","author":"Veitch","year":"2021","journal-title":"J Natl Cancer Inst"},{"issue":"19","key":"coi250077r20","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1093\/jnci\/djt242","article-title":"Recommendations for high-priority research on cancer-related fatigue in children and adults.","volume":"105","author":"Barsevick","year":"2013","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"coi250077r21","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1097\/00006199-200101000-00007","article-title":"An explanatory model of fatigue in women receiving adjuvant breast cancer chemotherapy.","volume":"50","author":"Berger","year":"2001","journal-title":"Nurs Res"},{"issue":"3","key":"coi250077r22","first-page":"465","article-title":"Symptom clusters and their effect on the functional status of patients with cancer.","volume":"28","author":"Dodd","year":"2001","journal-title":"Oncol Nurs Forum"},{"issue":"8","key":"coi250077r24","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1111\/j.1524-4733.2009.00600.x","article-title":"Good research practices for comparative effectiveness research: defining, reporting and interpreting nonrandomized studies of treatment effects using secondary data sources: the ISPOR Good Research Practices for Retrospective Database Analysis Task Force Report\u2013Part I.","volume":"12","author":"Berger","year":"2009","journal-title":"Value Health"},{"issue":"3","key":"coi250077r25","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1200\/JCO.1993.11.3.570","article-title":"The Functional Assessment of Cancer Therapy scale: development and validation of the general measure.","volume":"11","author":"Cella","year":"1993","journal-title":"J Clin Oncol"},{"issue":"6","key":"coi250077r26","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1016\/j.jpainsymman.2007.01.016","article-title":"Validation of single-item linear analog scale assessment of quality of life in neuro-oncology patients.","volume":"34","author":"Locke","year":"2007","journal-title":"J Pain Symptom Manage"},{"issue":"5","key":"coi250077r27","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/S0025-6196(11)62218-0","article-title":"Assessing the clinical significance of single items relative to summated scores.","volume":"77","author":"Sloan","year":"2002","journal-title":"Mayo Clin Proc"},{"issue":"12","key":"coi250077r29","doi-asserted-by":"crossref","first-page":"3375","DOI":"10.1007\/s11136-019-02289-4","article-title":"Psychometric properties of the PROMIS Fatigue Short Form 7a among adults with myalgic encephalomyelitis\/chronic fatigue syndrome.","volume":"28","author":"Yang","year":"2019","journal-title":"Qual Life Res"},{"issue":"7","key":"coi250077r30","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1002\/1097-0142(20001001)89:7<1634::AID-CNCR29>3.0.CO;2-V","article-title":"Assessing symptom distress in cancer patients: the M.D. Anderson Symptom Inventory.","volume":"89","author":"Cleeland","year":"2000","journal-title":"Cancer"},{"issue":"5","key":"coi250077r31","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","article-title":"The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology.","volume":"85","author":"Aaronson","year":"1993","journal-title":"J Natl Cancer Inst"},{"issue":"5","key":"coi250077r32","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1097\/00002820-197810000-00003","article-title":"Development of a symptom distress scale.","volume":"1","author":"McCorkle","year":"1978","journal-title":"Cancer Nurs"},{"issue":"2","key":"coi250077r33","first-page":"111","article-title":"Cancer statistics for African American and Black people, 2025.","volume":"75","author":"Saka","year":"2025","journal-title":"CA Cancer J Clin"},{"issue":"3","key":"coi250077r34","doi-asserted-by":"crossref","first-page":"E290","DOI":"10.1152\/ajpendo.00378.2023","article-title":"Metabolic underpinnings of cancer-related fatigue.","volume":"326","author":"Zhang","year":"2024","journal-title":"Am J Physiol Endocrinol Metab"},{"issue":"13","key":"coi250077r35","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1200\/JCO.21.02377","article-title":"Sex differences in risk of severe adverse events in patients receiving immunotherapy, targeted therapy, or chemotherapy in cancer clinical trials.","volume":"40","author":"Unger","year":"2022","journal-title":"J Clin Oncol"},{"issue":"9","key":"coi250077r38","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/dju244","article-title":"Development of the National Cancer Institute\u2019s patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE).","volume":"106","author":"Basch","year":"2014","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"coi250077r39","doi-asserted-by":"crossref","first-page":"12815","DOI":"10.1038\/s41598-023-39046-0","article-title":"Prevalence of cancer-related fatigue based on severity: a systematic review and meta-analysis.","volume":"13","author":"Kang","year":"2023","journal-title":"Sci Rep"},{"issue":"2","key":"coi250077r40","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1001\/jama.2017.7156","article-title":"Overall survival results of a trial assessing patient-reported outcomes for symptom monitoring during routine cancer treatment.","volume":"318","author":"Basch","year":"2017","journal-title":"JAMA"},{"issue":"4","key":"coi250077r41","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1038\/s41591-025-03507-y","article-title":"Symptom monitoring with electronic patient-reported outcomes during cancer treatment: final results of the PRO-TECT cluster-randomized trial.","volume":"31","author":"Basch","year":"2025","journal-title":"Nat Med"},{"issue":"3","key":"coi250077r42","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1200\/JCO.2013.48.6662","article-title":"Electronic self-report assessment for cancer and self-care support: results of a multicenter randomized trial.","volume":"32","author":"Berry","year":"2014","journal-title":"J Clin Oncol"},{"key":"coi250077r43","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1186\/1472-6963-13-211","article-title":"A systematic review of the impact of routine collection of patient reported outcome measures on patients, providers and health organisations in an oncologic setting.","volume":"13","author":"Chen","year":"2013","journal-title":"BMC Health Serv Res"},{"issue":"3","key":"coi250077r44","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1001\/jama.2018.18085","article-title":"Two-year survival comparing web-based symptom monitoring vs routine surveillance following treatment for lung cancer.","volume":"321","author":"Denis","year":"2019","journal-title":"JAMA"},{"key":"coi250077r45","article-title":"eSyM: an electronic health record-integrated patient-reported outcomes-based cancer symptom management program used by six diverse health systems.","volume":"6","author":"Hassett","year":"2022","journal-title":"JCO Clin Cancer Inform"},{"issue":"4","key":"coi250077r46","doi-asserted-by":"crossref","first-page":"e442","DOI":"10.1200\/OP.21.00407","article-title":"Association between health-related quality of life and progression-free survival in patients with advanced cancer: a secondary analysis of SWOG clinical trials.","volume":"18","author":"Hui","year":"2022","journal-title":"JCO Oncol Pract"},{"issue":"2","key":"coi250077r48","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s11864-020-0707-5","article-title":"Cancer-related fatigue: causes and current treatment options.","volume":"21","author":"Thong","year":"2020","journal-title":"Curr Treat Options Oncol"},{"key":"coi250077r49","doi-asserted-by":"crossref","DOI":"10.1016\/j.neubiorev.2025.106035","article-title":"The metabolic basis of cancer-related fatigue.","volume":"169","author":"Dantzer","year":"2025","journal-title":"Neurosci Biobehav Rev"},{"issue":"10","key":"coi250077r50","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1038\/nrclinonc.2014.127","article-title":"Cancer-related fatigue\u2013mechanisms, risk factors, and treatments.","volume":"11","author":"Bower","year":"2014","journal-title":"Nat Rev Clin Oncol"},{"issue":"8","key":"coi250077r51","doi-asserted-by":"crossref","first-page":"1982","DOI":"10.3390\/cancers14081982","article-title":"A new approach to understanding cancer-related fatigue: leveraging the 3P model to facilitate risk prediction and clinical care.","volume":"14","author":"Sleight","year":"2022","journal-title":"Cancers (Basel)"},{"key":"coi250077r52","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1111\/j.1749-6632.2012.06634.x","article-title":"Role of interleukin-6 in stress, sleep, and fatigue.","volume":"1261","author":"Rohleder","year":"2012","journal-title":"Ann N Y Acad Sci"},{"issue":"9","key":"coi250077r53","doi-asserted-by":"crossref","first-page":"2759","DOI":"10.1158\/1078-0432.CCR-05-2398","article-title":"Inflammatory biomarkers for persistent fatigue in breast cancer survivors.","volume":"12","author":"Collado-Hidalgo","year":"2006","journal-title":"Clin Cancer Res"},{"issue":"3","key":"coi250077r54","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.leukres.2012.11.013","article-title":"Correlation between cytokine levels and changes in fatigue and quality of life in patients with acute myeloid leukemia.","volume":"37","author":"Fung","year":"2013","journal-title":"Leuk Res"},{"issue":"4","key":"coi250077r55","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1002\/cncr.21234","article-title":"Cognitive impairment, fatigue, and cytokine levels in patients with acute myelogenous leukemia or myelodysplastic syndrome.","volume":"104","author":"Meyers","year":"2005","journal-title":"Cancer"},{"key":"coi250077r56","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2147\/CMAR.S115835","article-title":"Association of fatigue and depression with circulating levels of proinflammatory cytokines and epidermal growth factor receptor ligands: a correlative study of a placebo-controlled fatigue trial.","volume":"9","author":"Rich","year":"2017","journal-title":"Cancer Manag Res"},{"issue":"2","key":"coi250077r57","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1158\/1078-0432.CCR-08-0149","article-title":"Targeting inflammatory pathways for prevention and therapy of cancer: short-term friend, long-term foe.","volume":"15","author":"Aggarwal","year":"2009","journal-title":"Clin Cancer Res"},{"issue":"2","key":"coi250077r58","doi-asserted-by":"crossref","first-page":"456S","DOI":"10.1093\/ajcn\/83.2.456S","article-title":"Inflammation and cardiovascular disease mechanisms.","volume":"83","author":"Libby","year":"2006","journal-title":"Am J Clin Nutr"},{"issue":"4","key":"coi250077r59","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.jcf.2015.03.003","article-title":"Inflammation in cystic fibrosis lung disease: pathogenesis and therapy.","volume":"14","author":"Cantin","year":"2015","journal-title":"J Cyst Fibros"},{"issue":"5","key":"coi250077r60","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1056\/NEJM200108023450506","article-title":"Autoimmune diseases.","volume":"345","author":"Davidson","year":"2001","journal-title":"N Engl J Med"},{"issue":"14","key":"coi250077r61","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.2174\/1381612824666180327170632","article-title":"The role of inflammation in neurological disorders.","volume":"24","author":"Degan","year":"2018","journal-title":"Curr Pharm Des"},{"issue":"26","key":"coi250077r62","doi-asserted-by":"crossref","first-page":"3889","DOI":"10.2174\/138161212802083716","article-title":"Reactive oxygen species, inflammation, and lung diseases.","volume":"18","author":"Rosanna","year":"2012","journal-title":"Curr Pharm Des"},{"key":"coi250077r63","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1267091","article-title":"The role of inflammation in autoimmune disease: a therapeutic target.","volume":"14","author":"Xiang","year":"2023","journal-title":"Front Immunol"},{"issue":"6917","key":"coi250077r64","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1038\/nature01322","article-title":"Inflammation and cancer.","volume":"420","author":"Coussens","year":"2002","journal-title":"Nature"},{"issue":"20","key":"coi250077r65","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1200\/JCO.24.00541","article-title":"Management of fatigue in adult survivors of cancer: ASCO-Society for Integrative Oncology Guideline update.","volume":"42","author":"Bower","year":"2024","journal-title":"J Clin Oncol"},{"issue":"7","key":"coi250077r67","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1001\/jamaoncol.2016.6914","article-title":"Comparison of pharmaceutical, psychological, and exercise treatments for cancer-related fatigue: a meta-analysis.","volume":"3","author":"Mustian","year":"2017","journal-title":"JAMA Oncol"},{"issue":"1","key":"coi250077r68","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1038\/s41746-024-01387-z","article-title":"Randomized clinical trial of a digital integrative medicine intervention among patients undergoing active cancer treatment.","volume":"8","author":"Mao","year":"2025","journal-title":"NPJ Digit Med"},{"issue":"3","key":"coi250077r69","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1002\/cncr.31790","article-title":"The role of neuro-immune interactions in cancer-related fatigue: biobehavioral risk factors and mechanisms.","volume":"125","author":"Bower","year":"2019","journal-title":"Cancer"},{"issue":"10","key":"coi250077r70","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1093\/jnci\/djaf062","article-title":"Effects of exercise on inflammation in female survivors of nonmetastatic breast cancer: a systematic review and meta-analysis.","volume":"117","author":"Bettariga","year":"2025","journal-title":"J Natl Cancer Inst"},{"key":"coi250077r71","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1186\/s13063-015-1023-4","article-title":"A literature review on the representativeness of randomized controlled trial samples and implications for the external validity of trial results.","volume":"16","author":"Kennedy-Martin","year":"2015","journal-title":"Trials"},{"issue":"3","key":"coi250077r72","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/dju002","article-title":"Comparison of survival outcomes among cancer patients treated in and out of clinical trials.","volume":"106","author":"Unger","year":"2014","journal-title":"J Natl Cancer Inst"},{"key":"coi250077r23","unstructured":"US National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE). Accessed June 4, 2025. https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/ctc.htm"},{"key":"coi250077r28","unstructured":"HealthMeasures. PROMIS Short Form v1.0-Fatigue 7a. Accessed July 14, 2025. https:\/\/www.healthmeasures.net\/index.php?option=com_instruments&view=measure&id=160?"},{"key":"coi250077r36","unstructured":"US National Institutes of Health. National Cancer Institute: Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE). Accessed June 6, 2025. https:\/\/healthcaredelivery.cancer.gov\/pro-ctcae\/"},{"key":"coi250077r37","unstructured":"US National Cancer Institute. Division of Cancer Control & Population Sciences: Correspondence Between PRO-CTCAE and CTCAE Terminologies. Accessed June 6, 2025. https:\/\/healthcaredelivery.cancer.gov\/pro-ctcae\/terms.html"},{"key":"coi250077r47","unstructured":"US National Cancer Institute. Fatigue. Accessed July 11, 2025. https:\/\/www.cancer.gov\/publications\/dictionaries\/cancer-terms\/def\/fatigue"},{"key":"coi250077r66","unstructured":"US National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Cancer-Related Fatigue, version 1. Accessed October 14, 2025. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/fatigue.pdf"}],"container-title":["JAMA Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/articlepdf\/2843277\/jamaoncology_unger_2025_oi_250077_1771446067.47261.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T16:01:01Z","timestamp":1771516861000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/fullarticle\/2843277"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,1]]},"references-count":72,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaoncol.2025.5549","relation":{},"ISSN":["2374-2437"],"issn-type":[{"value":"2374-2437","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2,1]]}}}